Ha Noi CPC1 Pharmaceutical JSC

The company maintains a strong liquidity position, with a current ratio of 2.69, indicating that it has more than double the current assets to cover its short-term liabilities. However, its net cash position is negative after subtracting total debt, which raises some liquidity concerns. The company's debt-to-equity ratio is 0.12, suggesting a relatively conservative capital structure with limited leverage.

In terms of profitability, the company's return on equity (ROE) is 7.49%, and its return on assets (ROA) is 5.46%. These figures are in line with the industry's preferred metrics, which emphasize asset efficiency and equity returns. The company's operating margin, calculated as operating income divided by revenue, is 22.12%, which is a strong indicator of cost control and pricing power.

The company's revenue is concentrated in a single geographic market, Vietnam, which exposes it to local economic and regulatory risks. There is no disclosed segmental breakdown of revenue, so it is unclear whether the company operates in multiple therapeutic areas or product lines. This lack of diversification could limit its ability to adapt to market changes or expand into new regions.

Looking ahead, the company's growth trajectory is expected to remain stable, with no significant changes in revenue or profitability projected for the next fiscal year. The company's capital expenditures are negative, indicating that it is not investing in new assets, which may suggest a focus on maintaining existing operations rather than expanding. This could be a strategic decision to preserve cash or a sign of limited growth opportunities.

The company's risk profile is moderate, with a low dilution potential and a medium liquidity risk. The risk assessment highlights the negative net cash position as a key flag, which could impact the company's ability to fund operations or respond to unexpected challenges. There are no recent filings or transcripts indicating significant events that would alter the company's risk profile or strategic direction.

There are no recent events or disclosures that would suggest a material change in the company's operations, strategy, or financial position. The company has not issued any new shares or announced any major transactions that would affect its capital structure or market position. This stability may be a positive for investors seeking predictable performance, but it could also indicate a lack of innovation or expansion plans.

Revenue grew 31.1% year-over-year to nearly 1.7 trillion VND, demonstrating strong top-line expansion momentum.

Low debt-to-equity ratio of 0.12 suggests a conservative capital structure with minimal leverage risk.

Cash conversion ratio of 0.77 falls below the pharmaceutical cohort median of 0.95, indicating weaker cash efficiency.

Medium liquidity risk flags potential challenges in meeting short-term obligations despite strong profitability metrics.